Analysts raised ratings and price objectives for Johnson & Johnson following a Form 13F filing with the SEC.

2 reports, 2 independent Updated Jun 11

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Analysts raised ratings and price objectives for Johnson & Johnson following a Form 13F filing with the SEC.

Who's involved

What this event is mainly about

Johnson & Johnson

Keep exploring

Part of

Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC. All 4 developments

The entities involved

Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- Microsoft and Alphabet are funding the AI boom, while TRACE pricing data is used for bond comparisons and both companies hold AAA ratings.09:15
- Gardiner Harris's investigative reporting led to fraud fines against Bristol-Myers Squibb and a book dissecting Johnson & Johnson scandals.01:35

Coverage

Newest first; wire copies grouped

Jun 11dailypolitical.com
Jun 10yahoo.com